AMRX · Amneal Pharmaceuticals, Inc.
Market Cap
$5.57B
Shares
319.35M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$3.02B
+8%
FY2025
Net Income
$72.06M
+161.6%
FY2025
Gross Margin
36.88%
+0.4pp
FY2025
Operating Margin
13.05%
+4.1pp
FY2025
Diluted EPS
$0.22
+157.9%
FY2025
Operating Cash Flow
$339.99M
+15.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.12B | $3.02B | $2.79BG | $2.39B | $2.21BG | $2.09BG | $1.99B | $1.63B | $1.66B | $1.03B | $1.02B | |
| $1.89B | $1.91B | $1.77B | $1.57B | $1.43B | $1.32B | $1.33B | $1.15B | $938.77M | $507.48M | $420.77M | |
| $1.23B | $1.11B | $1.02B | $820.57M | $784.71M | $768.97M | $628.39M | $353M | $716.4M | $526.18M | $597.46M | |
| — | 36.88% | 36.52% | 34.28% | 35.47% | 36.73% | 31.54% | 21.7% | 43.08% | 50.9% | 58.68% | |
| $175.57M | $186.18M | $190.71M | $163.95M | $195.69M | $201.85M | $179.93M | $188.05M | $194.19M | $171.42M | $179.02M | |
| $571.86M | $526.83M | $476.44M | $429.68M | $399.7M | $365.5M | $326.73M | $289.6M | $227.85M | $109.05M | $118.76M | |
| $140.2M | $166.3M | $173.6M | $163.2M | $172.1M | $172.7M | $174.97M | $143.95M | $143.95M | $72.99M | $3.7M | |
| $3.82M | $4.21M | $2.36M | $1.75M | $1.42M | $1.86M | $2.4M | $34.35M | $56.41M | $0 | $0 | |
| $453.92M | $394.1M | $249.33M | $204.37M | -$94.93M | $152.72M | $91.16M | -$248.68M | -$19.67M | $245.1M | $284.88M | |
| — | 13.05% | 8.92% | 8.54% | -4.29% | 7.29% | 4.57% | -15.29% | -1.18% | 23.71% | 27.98% | |
| -$252.74M | -$254.89M | -$304.34M | -$244.64M | -$153.2M | -$121.35M | -$126.94M | $28.44M | -$183.05M | -$73.78M | -$70.06M | |
| $201.18M | $139.21M | -$55.01M | -$40.27M | -$248.13M | $31.37M | -$35.78M | -$220.24M | -$202.72M | $171.32M | $214.82M | |
| -$14.14M | $11.28M | $18.86M | $8.45M | $6.66M | $11.2M | -$104.36M | $383.33M | -$1.42M | $2M | $5.4M | |
| $157.36M | $72.06M | -$116.89M | -$83.99M | -$270.58M | $13.16M | $67.79M | -$603.57M | -$19.74M | $0 | $0 | |
| — | 2.39% | -4.18% | -3.51% | -12.23% | 0.63% | 3.4% | -37.11% | -1.19% | 0% | 0% | |
| $57.96M | $55.88M | $43.01M | $35.27M | -$125.24M | $9.55M | -$22.48M | -$241.66M | -$32.75M | $1.68M | $2.05M | |
| $157.36M | $72.06M | -$116.89M | -$83.99M | -$129.99M | $10.62M | $91.06M | -$361.92M | -$20.92M | $0 | $0 | |
| $154.13M | $26.84M | -$150.05M | -$127.04M | -$95.11M | $27.34M | $49.86M | -$353.42M | -$23.34M | $0 | $0 | |
| USD/shares | $0.50 | $0.23 | -$0.38 | -$0.48 | -$0.86 | $0.07 | $0.62 | -$2.74 | -$0.16 | — | — |
| USD/shares | $0.48 | $0.22 | -$0.38G | -$0.48 | -$0.86G | $0.07G | $0.61 | -$2.74 | -$0.16 | — | — |
| shares | — | 313.37M | 308.98M | 176.14M | 150.94M | 148.92M | 147.44M | 132.11M | 127.25M | — | — |
| shares | — | 324.81M | 308.98M | 176.14M | 150.94M | 151.82M | 148.91M | 132.11M | 127.25M | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2020: $758.88M in dividends.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
2.57×
Peer median 2.34×
EV/EBIT
17.65×
Peer median 21.72×
P/E (TTM)
36.33×
Peer median 16.45×
Peer medians compare against the 37 similar-size Drug Manufacturers - Specialty & Generic companies (of 100 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Affordable Medicines Segment | $1,745,524,000 | $1,685,263,000 | $1,471,401,000 | $1,432,073,000 | — | — | — | — |
| AvKARE Segment | $744,728,000 | $662,945,000 | $531,749,000 | $406,110,000 | $349,012,000 | $293,746,000 | — | — |
| Specialty Segment | $528,508,000 | $445,749,000 | $390,457,000 | $374,121,000 | $378,319,000 | $355,567,000 | $317,530,000 | $223,960,000 |
| Amneal Specialty Pharma Segment | — | — | — | $374,121,000 | $378,319,000 | $355,567,000 | $317,530,000 | $223,960,000 |
| Av Kare | — | — | — | — | $349,012,000 | $293,746,000 | $0 | $0 |
| Generics Segment | — | — | $1,471,401,000 | $1,432,073,000 | $1,366,338,000 | $1,343,210,000 | $1,308,843,000 | $1,439,031,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $1,745,524,000 | $1,685,263,000 | $1,471,401,000 | $1,432,073,000 | — | — | $1,602,914,000 | $1,602,997,000 |
| Non Us | — | — | $2,165,000 | $1,468,000 | $1,299,000 | $2,333,000 | $20,600,000 | $59,700,000 |
By Product & Service (USD)
| Component | FY2019 | FY2018 | FY2017 |
|---|---|---|---|
| Royalties | $2,859,000 | $294,000 | $12,522,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Affordable Medicines Segment | $380,798,000 | $270,104,000 | $276,170,000 | $224,156,000 | — | — | — | — |
| Specialty Segment | $116,002,000 | $113,580,000 | $65,298,000 | $72,592,000 | $56,424,000 | — | — | — |
| AvKARE Segment | $83,615,000 | $42,901,000 | $31,512,000 | $3,318,000 | $6,798,000 | -$7,658,000 | — | — |
| Amneal Specialty Pharma Segment | — | — | — | $72,592,000 | $56,424,000 | $56,535,000 | $42,781,000 | $55,560,000 |
| Av Kare | — | — | — | — | $6,798,000 | -$7,658,000 | — | — |
| Generics Segment | — | — | $276,170,000 | $224,156,000 | $281,493,000 | $189,356,000 | -$133,151,000 | $162,901,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Affordable Medicines Segment | 21.8% | 16% | 18.8% | 15.7% | — | — | — | — |
| AvKARE Segment | 11.2% | 6.5% | 5.9% | 0.8% | 1.9% | -2.6% | — | — |
| Specialty Segment | 21.9% | 25.5% | 16.7% | 19.4% | 14.9% | — | — | — |
| Amneal Specialty Pharma Segment | — | — | — | 19.4% | 14.9% | 15.9% | 13.5% | 24.8% |
| Av Kare | — | — | — | — | 1.9% | -2.6% | — | — |
| Generics Segment | — | — | 18.8% | 15.7% | 20.6% | 14.1% | -10.2% | 11.3% |
Key facts
CIK
1723128
CUSIP
03168L105
13F (30d)
211 filings
210 filers
Visit website
Investor relations